AMLX

26.0100.73%
CL

Camille L. Bedrosian

Chief Medical Officer

Dr. Camille L. Bedrosian, M.D., serves as Chief Medical Officer at Amylyx Pharmaceuticals, Inc. since November 2023. Dr. Bedrosian had been a Director at Rhythm Pharmaceuticals, Inc. since December 9, 2020 until December 16, 2025 and served as its Independent Director until December 16, 2025. Dr. Bedrosian served as Independent Director at Crinetics Pharmaceuticals, Inc. since September 2020 until September 1, 2026. She had been the Chief Medical Officer and Executive Vice President at Ultragenyx Pharmaceutical Inc., since January 29, 2018 until May 01, 2023, where she oversaw global development functions including medical affairs, clinical development, clinical operations, regulatory affairs, patient advocacy and engagement, biometrics and drug safety/pharmacovigilance. Prior to Ultragenyx, Dr. Bedrosian held executive-level positions in global development at Alexion Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc. She has extensive experience leading drug development efforts for rare disease products and building successful medical affairs and clinical development teams. Dr. Bedrosian served as Chief Medical Officer and Senior Vice President of Alexion Pharmaceuticals, Inc. since May 2008 until December 2017, where she provided leadership for the development of drugs and drug candidates including those designed to address devastating rare diseases such as Soliris(r) (eculizumab). Dr. Bedrosian has more than 25 years of medical practice, research and drug development experience. Dr. Bedrosian has global responsibility for aspects of clinical research, such as clinical operations, clinical data management, medical affairs and pharmacovigilance. She served as Chief Medical Officer and Vice President of Ariad Pharmaceuticals Inc., from September 2002 to April 2008. From 1997 to 2002, Dr. Bedrosian served in the Clinical Research and Development Department of Wyeth/Genetics Institute, Inc. From 1997 to 2002, Dr. Bedrosian was the Senior Director of Oncology, Hematology and Therapeutic Area and Director for Hemophilia at Genetics Institute, LLC. From 1986 to 1997, she was a Fellow, an Associate and Assistant Professor of Medicine in the Division of Hematology and Oncology at Duke University Medical Center and the Duke Comprehensive Cancer Center Since December 2020. Dr. Bedrosian is the author of numerous research publications, patents, presentations and abstracts and is a member of several professional associations, including the American Association for Cancer Research, American Association for the Advancement of Sciences, American Society of Clinical Oncology and American Society of Hematology. In 2005, she was recipient of the Symbol of Caring Award from the Sarcoma Foundation of America. Dr. Bedrosian received her A.B. degree from Harvard University/Radcliffe College in Chemistry, her M.S. in Biophysics from M.I.T. and her M.D. from Harvard Medical School.

Positions